DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0087900 A1 Telerman Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0087900 A1 Telerman Et Al US 20030087900A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0087900 A1 Telerman et al. (43) Pub. Date: May 8, 2003 (54) DRUGS WHICH CAN BE USED IN THE Related U.S. Application Data TREATMENT OF CANCER (63) Continuation of application No. 09/885,031, filed on Jun. 20, 2001, now abandoned. (75) Inventors: Adam Telerman, Paris (FR); Robert Amson, Paris (FR); Marius Tuijnder, (30) Foreign Application Priority Data Mechelen (BE) Jun. 1, 2001 (FR)............................................ 01/07285 Correspondence Address: Publication Classification PENNIE & EDMONDS LLP 7 1667 K Street, N.W. (51) Int. Cl. ...................... A61K 3.1/542; A61K 31/495 Washington, DC 20006 (US) (52) U.S. Cl. ................................... 514/225.2; 514/255.04 (57) ABSTRACT (73) Assignee: Molecular Engines Laboratories The present invention relates to the use of a compound (21)21) AppAppl. No.: 10,304,964/304, Inhibitinginhibiting ththe eXpreSSLOnpressi Off the TPT1 g ene, or off theth products which it controls, for producing a drug which is (22) Filed: Nov. 27, 2002 intended for treating cancer. Patent Application Publication May 8, 2003 Sheet 1 of 10 US 2003/0087900 A1 20 100 68 OO 4. O 2 O 1.9 0.0 3.4 O O Control A 100 A B 1OO B C 100 C D 100 D 1000 1 OOO 1000 1000 FG. A 120 113.5 100 80 60 40 20 E-- Control A 100 A B 100 B C 100 C D 1 OO D 1000 1000 1000 1000 FIG.1B Patent Application Publication May 8, 2003 Sheet 2 of 10 US 2003/0087900 A1 20 1 OO 100 69.7 100.0 8 O 6 O w 4. O 2 O 11.6 - 0.0 % O M Control A 100 A B 100 B C 100 C D 100 D 1000 1 OOO 1000 1000 FIG.2A 120 100 8 O 2 O O Control A 100 A B 100 B C 100 C 000 1000 1000 FIG.2B Patent Application Publication May 8, 2003 Sheet 3 of 10 US 2003/0087900 A1 Patent Application Publication May 8, 2003 Sheet 4 of 10 US 2003/0087900 A1 1200 100.0 80.0 60.0 40.0 8 20.0 : X : : 0.0 Control A 100 A 1000 B OO B 000 C 100 C 1000 D 100 D 1000 FIG.4A Patent Application Publication May 8, 2003 Sheet 5 of 10 US 2003/0087900 A1 120.0 100.0 80.0 60.0 40.0 20.0 s - -- 0.0 Control A 100 A 1000 B 100 B 1000 C 100 C 1000 D 100 D 1000 FG.5A 100.0 Patent Application Publication May 8, 2003 Sheet 6 of 10 US 2003/0087900 A1 Control A 100 A 1000 B 100 B 1000 C 100 C 1000 D 100 D 1000 FIG.6A Patent Application Publication May 8, 2003 Sheet 7 of 10 US 2003/0087900 A1 1 OOO 100.0 90.0 80.0 700 60.0 50.0 43.3 40.0 Ž 30.0 1 O.O O O.O 1 Control A 100 A 1000 B 100 B 1OOO C 100 ( 1000 D iOOD 1 000 FG./A 100.0 Patent Application Publication May 8, 2003 Sheet 8 of 10 US 2003/0087900 A1 2 322 2 Control A 1000 A 2000 A 5000 C 1000 C 2000 C 5000 FG.8A 100.0 97.1 a W. Contro A OOO. A 2000. A 5000 C 1000 C 2000 C 5000 FIG.8B Patent Application Publication May 8, 2003 Sheet 9 of 10 US 2003/0087900 A1 120.0 100 u? 100.0 84.5 85.0 77.5 s , 80.0 71.7 % 60.0 is 40.0 30.5 20.0 O.O -- - 2 control A 1000 A 2000 A 5000 C 1000 C 2000 C 5000 FG.9 Patent Application Publication May 8, 2003 Sheet 10 of 10 US 2003/0087900 A1 120.0 2 100.0 80.0 60.0 40.0 20.0 0.0 Control A 1000 A 2000 A 5000 C 1000 C 2000 C 5000 F.G. 1 OA 120.0 100.0 80.0 60.0 40.0 20.0 O.0 Control A 1000 A 2000 A 5000 C 1000 C 2000 C 5000 FIG.10B US 2003/0O87900 A1 May 8, 2003 DRUGS WHICH CAN BE USED IN THE 0013 Those phenothiazine derivatives which may be TREATMENT OF CANCER mentioned are dimethothiazine, hydroxyethylpromethazine, isothipendyl, mecquitazine, methdilazine, oxomemazine, 0001. The present invention relates to the use of novel promethazine, propiomazine, thiazinamium and trimepra classes of compounds which are designed for producing a drug which is intended for treating cancer. ZC. 0014 Those piperazine derivatives which may in particu 0002 Research carried out by the applicant, in particular lar be mentioned are buclizine, cetirizine, chlorcyclizine, in the context of the phenomenon of tumor reversion, has led cinnarizine, clocinizine, cyclizine, flumarizine, homochlor to the demonstration that certain genes are overexpressed cycline, hydroxy Zine, meclozine, niaprazine and Oxatomide. during the tumor phase as compared with the reversion phase. 0015 Those ethanolamine derivatives which may be mentioned, in particular, are the phenhydramine derivatives 0003. The overexpression of one of these genes, i.e. the Such as bromodiphenhydramine and diphenhydramine and gene TPT1, standing for “translationally controlled tumor their homologues. protein encoding histamine releasing factor', demonstrated that the expression of this gene was Strongly decreased 0016. The ethylendiamines which may be mentioned are, during tumor reversion. for example, the compounds of the mepyramine type. 0004 Thus, a tumor cell line designated U937 is capable 0017 Finally, examples of the various compounds which of reverting and thereby resulting in what is termed a US do not have a Sedative component and which may be cell, that is to Say a cell line which no longer exhibits Such mentioned are acrivastine, ebastine, taZifyline and terfena a pronounced malignant phenotype characteristic. dine. 0005. In the U937 cell line, out of 2 000 sequences, for 0018. These compounds only represent the basic mol example, the number of clones for the TPT1 gene was 248 ecules which can be used in accordance with the present whereas it was no more than 2 in the US cell line. invention; it is also possible to use derivatives, in particular Substitution derivatives, of the abovementioned compounds, 0006. This has led the applicant to focus on the impor as well as physiologically acceptable Salts. tance of the histamine activation pathway in the phenom 0019. According to the present invention, treatment of enon of tumor reversion and to demonstrate the activity of the cancer is essentially understood as being the ability of a products which interfere with this pathway as a way of compound to Selectively destroy the tumor cells without treating cancer. appreciably affecting healthy cells, it being understood that 0007 More specifically, the present invention relates to this Selectivity can vary depending on the compounds and the use of compounds which totally or partially inhibit the depending on the condition of the patient and the type of expression of the TPT1 gene, or of the products which it cancer being treated. controls, for the purpose of producing a drug which is 0020. As will be observed in the examples which follow, intended for treating cancer. the products according to the present invention exhibit 0008. The present invention naturally relates not only to remarkable Selectivity and, in particular, a very great ability the possibility of inhibiting the expression of the TPT1 gene to destroy tumor cells, in particular, the results have been in the cell but also to that of totally or partially inhibiting the found to be particularly impressive in relation to cells of the expression of the products whose metabolic chain it controls leukemic type and in relation to breast cancer, ductal carci directly or indirectly, up to and including the release of noma and carcinoma of the mammary glands. histamine, in particular. 0021. The compounds according to the present invention 0009 Among the compounds which can be used within can be used in the form of pharmaceutical compositions the context of the present invention, those which may more which may be employed by any route of administration; Specifically be mentioned are the antihistamines, that is to however, in a general manner, preference will be given to Say the antagonists of the histamine H1 receptors, in par using injectable routes, in particular, for treating tumors. It ticular. is, of course, possible to use other galenic forms, in particu lar the oral route. The daily doses have to take account of the 0010. It should be clearly understood that the antine compound, the condition of the patient and the nature and oplastic function of these compounds may be linked to Stage of the cancer being treated. Subsidiary elements of the cell, taking into account the fact that, for example, one of the antihistamine prototypes, i.e. 0022. The appended results demonstrate that there is a polaramine, is inactive within the context of the present dose above which the product loses most of its activity. invention. 0023. It is also possible to envisage using the compounds 0.011 Among these compounds which can be used within according to the present invention in combination with other the present invention, those which may very particularly be antineoplastic agents, whether these be antimetabolites, mentioned are the phenothiazine derivatives and the deriva alkylating agents, Spindle poisons, intercalating agents or tives of the piperazine type. other types of hormonal cytolytic agents or antineoplastic agents, as well as certain proteins Such as interferons in 0012.
Load more

Recommended publications
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Malaysian Statistics on Medicines 2007
    MALAYSIAN STATISTICS ON MEDICINES 2007 Edited by: Faridah AMY, Sivasampu S, Lian LM, Hazimah H, Kok LC, Chinniah RJ With contributions from Lian LM, Tang RY, Hafizh AA, Hazimah H, Gan HH, Kok LC, Leow AY, Lim JY, Thoo S, Hoo LP, Faridah AMY, Lim TO, Sivasampu S, Nour Hanah O, Fatimah AR, Nadia Fareeda MG, Goh A, Rosaida MS, Menon J, Radzi H, Yung CL, Michelle Tan HP, Yip KF, Chinniah RJ, Khutrun Nada Z, Masni M, Sri Wahyu T, Jalaludin MY, Leow NCW, Norafidah I, G R Letchuman R, Fuziah MZ, Mastura I, Sukumar R, Yong SL, Lim YX, Yap PK, Lim YS, Sujatha S, Goh AS, Chang KM, Wong SP, Omar I, Alan Fong YY, David Quek KL, Feisul IM, Long MS, Christopher Ong WM, Ghazali Ahmad, Abdul Rashid Abdul Rahman, Hooi LS, Khoo EM, Sunita Bavanandan, Nur Salima Shamsudin, Puteri Juanita Zamri, Sim KH, Wan Azman WA, Abdul Kahar AG, Faridah Y, Sahimi M, Haarathi C, Nirmala J, Azura MA, Asmah J, Rohna R, Choon SE, Roshidah B, Hasnah Z, Wong CW, Noorsidah MY, Sim HY, J Ravindran, Nik Nasri, Ghazali I, Wan Abu Bakar, Tham SW, J Ravichandran, Zaridah S, W Zahanim WY, Intan SS, Tan AL, Malek R, Sothilingam S, Syarihan S, Foo LK, Low KS, Janet YH Hong, Tan ATB, Lim PC, Loh YF, Nor Azizah, Sim BLH, Mohd Daud CY, Sameerah SAR, Muhd Nazri, Cheng JT, Lai J, Rahela AK, Lim GCC, Azura D, Rosminah MD, Kamarun MK, Nor Saleha IT, Tajunisah ME, Wong HS, Rosnawati Yahya, Manjulaa DS, Norrehan Abdullah, H Hussein, H Hussain, Salbiah MS, Muhaini O, Low YL, Beh PK, Cardosa MS, Choy YC, Lim RBL, Lee AW, Choo YM, Sapiah S, Fatimah SA, Norsima NS, Jenny TCN, Hanip R, Siti Nor
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Poison Or Antibiotic? a Guide to "Class" Entries
    Poison or Antibiotic? A Guide to “Class” Entries Preface Most entries in the Poisons List, i.e. the Schedule 10, and the Schedules 1, 2 and 3 to the Pharmacy and Poisons Regulations (Cap. 138A) are in the form of individual drugs and their salts, e.g. “Abacavir; its salts”. However, some entries are in the form of a “class”, e.g. “Barbituric acid; its salts; its derivatives …”. In such cases, it is not always clear which drugs are members of the class (e.g. amobarbital, barbital, pentobarbital, phenobarbital, etc. are poisons, being derivatives of barbituric acid). Likewise, the Antibiotics Ordinance (Cap. 137) applies to the substances specified in Schedule 1 to the Antibiotics Regulations, to their salts and derivatives, and to the salts of such derivatives. Again, it is not always clear which drugs are derivatives of an antibiotic named in the Schedule (e.g. demeclocycline, doxycycline, tigecycline, etc. are antibiotics, being derivatives of “Tetracycline” named in the Schedule). This Guide provides a list of such drugs which are available as registered pharmaceutical products in Hong Kong. Drugs which are not available as registered pharmaceutical products in Hong Kong are also included in this Guide as far as possible. It should be noted that it is not possible to compile a complete list of all these drugs, simply because there is no limit to the number of “derivatives” a parent chemical can have. This Guide should be read in conjunction with the Schedules 1, 2, 3, and 10 to the Pharmacy and Poisons Regulations, and Schedule 1 to the Antibiotics Regulations, if the poison/antibiotic classification of a particular pharmaceutical product is to be determined.
    [Show full text]
  • Atc Index 2010
    ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine
    [Show full text]
  • Mebhydrolin Napadisylate
    www.chemicalland21.com MEBHYDROLIN NAPADISYLATE SYNONYMS Diazolin; Diazoline; Mebhydroline 1,5-naphthalenedisulfonate salt; Diazolinum; Omeril; 5-Benzyl-1,3,4,5- tetrahydro-2-methyl-2H-pyrido(4,3-b)indole 1,5-naphthalenedisulfonate; 9-Benzyl-N-methyl-1,2,3,4- tetrahydro-alpha-carboline; Incidal; Mebhydroline napadisylate; PRODUCT IDENTIFICATION CAS RN 6153-33-9; 524-81-2 (Parent) EINECS RN 228-170-3 FORMULA (C19H20N2)2·C10H8O6S2 MOL WEIGHT 841.05 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to almost white crystalline powder MELTING POINT 280 C (Decomposes) BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Histamine H1-receptor antagonists are used to relieve the symptoms of an immediate allergic reaction. They have additional anti-inflammatory effects that could result from an inhibition of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-kappaB). The implication of the H1- receptor in these effects is controversial. Diphenhydramine is a first-generation H1-receptor antagonist while mizolastine and desloratadine are second-generation compounds. Mizolastine is also an inhibitor of 5-lipoxygenase (5-LO), an enzyme that has been involved in NF-kappaB activation. (source: http://www.ingentaconnect.com) Antihistamines are medicines used to stop the effects of a substance in the blood called histamine. Histamine is a natural chemical produced by the immune (disease-fighting) system of the body. When it is released, it increases blood flow to the affected area. Liquid leaks out of the blood vessels, causing the mucous membranes lining the nose and throat to swell, and stimulating the nearby gland to produce mucus.
    [Show full text]